Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.69 +8.33%
Revenue Growth %: +40.6%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: +40.6%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M
- Syra Health names Dr. Cori McMahon as fractional chief medical officer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
